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Background
 Tranexamic acid (TXA) is a synthetic 
antifibrinolytic that prevents fibrin 
breakdown by binding to plasminogen, 
thus stabilizing the fibrin clot.1
 Intraoperative use of TXA has proven to be 
effective in reducing transfusion 
requirements after spinal fusion.2,3
Background
 TXA can be administered 
orally, topically, or IV.
 IV TXA costs $47-$108 per dose 
depending on formulation.10
 Oral TXA is both cheaper and 
easier to administer than IV.
 There are currently no 
prospective studies 
investigating equivalence 
between IV and PO TXA in 
spinal fusion surgery.
Methods
 PO TXA: 1950mg (3 tablets) 2 hrs before incision
 IV TXA: 1g (in 100mL NS) bolus before incision and 1g 
before closure
 2 surgeons: G.G. performed majority of surgeries (95%)
 Revision cases: 63% of total
 Exclusion criteria: known allergy to TXA, history of renal failure or kidney transplant, 
history of arterial thromboembolic event (eg. myocardial infarction, stroke) within 
the past year, placement of an arterial stent within the past year, a history of 
thromboembolic event, coagulopathy, or refusal toreceive blood products.
A randomized, 
controlled trial


Results
Results
Results
Discussion
 PO TXA has been shown to be equivalent to IV in total 
joints literature
 First study comparing PO and IV TXA in thoracolumbar 
fusions
 Use of oral TXA in spinal fusion surgery could provide 
substantial savings to the healthcare system
 At least $20 million per year of saving
Limitations
 Heterogeneity in patient diagnosis and surgical 
technique/approach
 Hgb change was based on lowest recorded post-operative hgb, 
which could be affected by hemodilution
 No placebo group and assumed PO TXA was superior than 
placebo
Summary
 Oral TXA is equivalent to IV TXA in preventing blood loss 
and hemoglobin drop in spinal fusion surgery.
 There is no significant difference in drain output, post-op 
transfusions, DVT/PE, or infections when using IV or PO 
TXA.
 Oral TXA is a viable, more cost-effective alternative to IV 
TXA to prevent blood loss in spine surgery.
Future Directions
 Ongoing trial to collect a larger cohort to perform 
adequately powered sub-group analysis
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